Evidence map›Paper›PMID 35227694›Full record

Observational studyAmerican journal of ophthalmology2022

Hearing Dysfunction After Treatment With Teprotumumab for Thyroid Eye Disease.

Connie M Sears, Amee D Azad, Linus Amarikwa, Brandon H Pham, Clara J Men, Daniel N Kaplan, Jocelyn Liu, Andrew R Hoffman, Austin Swanson, Jennifer Alyono and 3 more

Open access · greenAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in American journal of ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 4 pooled it
10.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 4 syntheses or guidelines pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Patterns of Teprotumumab-Induced Hearing Dysfunction: A Systematic Review.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2025
    Pooled it
  4. Pooled it
  5. Hearing loss in hyperthyroid patients treated with teprotumumab (TepezzaEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Article
  6. Article
  7. Review
  8. Small-molecule IGF1R inhibitors extend healthspan in a mouse model.bioRxiv : the preprint server for biology · 2026
    Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Time to improvement following teprotumumab treatment of thyroid eye disease: real world experience.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Connie M SearsFrom the Department of Ophthalmology, Byers Eye Institute (C.M.S., A.D.A., L.A., B.H.P., C.J.M., J.L., A.L.K.); Department of Medicine-Endocrinology, Gerontology, & Metabolism (D.N.K., A.R.H., C.D.); and Department of Otolaryngology (A.S., J.A., J.Y.L.), Stanford University School of Medicine, Palo Alto, California, USA. Daniel Kaplan is an endocrinologist now practicing at Epic Care, San Leandro, California, USA.
Amee D AzadFrom the Department of Ophthalmology, Byers Eye Institute (C.M.S., A.D.A., L.A., B.H.P., C.J.M., J.L., A.L.K.); Department of Medicine-Endocrinology, Gerontology, & Metabolism (D.N.K., A.R.H., C.D.); and Department of Otolaryngology (A.S., J.A., J.Y.L.), Stanford University School of Medicine, Palo Alto, California, USA. Daniel Kaplan is an endocrinologist now practicing at Epic Care, San Leandro, California, USA.
Linus AmarikwaFrom the Department of Ophthalmology, Byers Eye Institute (C.M.S., A.D.A., L.A., B.H.P., C.J.M., J.L., A.L.K.); Department of Medicine-Endocrinology, Gerontology, & Metabolism (D.N.K., A.R.H., C.D.); and Department of Otolaryngology (A.S., J.A., J.Y.L.), Stanford University School of Medicine, Palo Alto, California, USA. Daniel Kaplan is an endocrinologist now practicing at Epic Care, San Leandro, California, USA.
Brandon H PhamFrom the Department of Ophthalmology, Byers Eye Institute (C.M.S., A.D.A., L.A., B.H.P., C.J.M., J.L., A.L.K.); Department of Medicine-Endocrinology, Gerontology, & Metabolism (D.N.K., A.R.H., C.D.); and Department of Otolaryngology (A.S., J.A., J.Y.L.), Stanford University School of Medicine, Palo Alto, California, USA. Daniel Kaplan is an endocrinologist now practicing at Epic Care, San Leandro, California, USA.
Clara J MenFrom the Department of Ophthalmology, Byers Eye Institute (C.M.S., A.D.A., L.A., B.H.P., C.J.M., J.L., A.L.K.); Department of Medicine-Endocrinology, Gerontology, & Metabolism (D.N.K., A.R.H., C.D.); and Department of Otolaryngology (A.S., J.A., J.Y.L.), Stanford University School of Medicine, Palo Alto, California, USA. Daniel Kaplan is an endocrinologist now practicing at Epic Care, San Leandro, California, USA.
Daniel N KaplanFrom the Department of Ophthalmology, Byers Eye Institute (C.M.S., A.D.A., L.A., B.H.P., C.J.M., J.L., A.L.K.); Department of Medicine-Endocrinology, Gerontology, & Metabolism (D.N.K., A.R.H., C.D.); and Department of Otolaryngology (A.S., J.A., J.Y.L.), Stanford University School of Medicine, Palo Alto, California, USA. Daniel Kaplan is an endocrinologist now practicing at Epic Care, San Leandro, California, USA.
Jocelyn LiuFrom the Department of Ophthalmology, Byers Eye Institute (C.M.S., A.D.A., L.A., B.H.P., C.J.M., J.L., A.L.K.); Department of Medicine-Endocrinology, Gerontology, & Metabolism (D.N.K., A.R.H., C.D.); and Department of Otolaryngology (A.S., J.A., J.Y.L.), Stanford University School of Medicine, Palo Alto, California, USA. Daniel Kaplan is an endocrinologist now practicing at Epic Care, San Leandro, California, USA.
Andrew R HoffmanFrom the Department of Ophthalmology, Byers Eye Institute (C.M.S., A.D.A., L.A., B.H.P., C.J.M., J.L., A.L.K.); Department of Medicine-Endocrinology, Gerontology, & Metabolism (D.N.K., A.R.H., C.D.); and Department of Otolaryngology (A.S., J.A., J.Y.L.), Stanford University School of Medicine, Palo Alto, California, USA. Daniel Kaplan is an endocrinologist now practicing at Epic Care, San Leandro, California, USA.
Austin SwansonFrom the Department of Ophthalmology, Byers Eye Institute (C.M.S., A.D.A., L.A., B.H.P., C.J.M., J.L., A.L.K.); Department of Medicine-Endocrinology, Gerontology, & Metabolism (D.N.K., A.R.H., C.D.); and Department of Otolaryngology (A.S., J.A., J.Y.L.), Stanford University School of Medicine, Palo Alto, California, USA. Daniel Kaplan is an endocrinologist now practicing at Epic Care, San Leandro, California, USA.
Jennifer AlyonoFrom the Department of Ophthalmology, Byers Eye Institute (C.M.S., A.D.A., L.A., B.H.P., C.J.M., J.L., A.L.K.); Department of Medicine-Endocrinology, Gerontology, & Metabolism (D.N.K., A.R.H., C.D.); and Department of Otolaryngology (A.S., J.A., J.Y.L.), Stanford University School of Medicine, Palo Alto, California, USA. Daniel Kaplan is an endocrinologist now practicing at Epic Care, San Leandro, California, USA.
Jennifer Y LeeFrom the Department of Ophthalmology, Byers Eye Institute (C.M.S., A.D.A., L.A., B.H.P., C.J.M., J.L., A.L.K.); Department of Medicine-Endocrinology, Gerontology, & Metabolism (D.N.K., A.R.H., C.D.); and Department of Otolaryngology (A.S., J.A., J.Y.L.), Stanford University School of Medicine, Palo Alto, California, USA. Daniel Kaplan is an endocrinologist now practicing at Epic Care, San Leandro, California, USA.
Chrysoula DosiouFrom the Department of Ophthalmology, Byers Eye Institute (C.M.S., A.D.A., L.A., B.H.P., C.J.M., J.L., A.L.K.); Department of Medicine-Endocrinology, Gerontology, & Metabolism (D.N.K., A.R.H., C.D.); and Department of Otolaryngology (A.S., J.A., J.Y.L.), Stanford University School of Medicine, Palo Alto, California, USA. Daniel Kaplan is an endocrinologist now practicing at Epic Care, San Leandro, California, USA.
Andrea L KosslerFrom the Department of Ophthalmology, Byers Eye Institute (C.M.S., A.D.A., L.A., B.H.P., C.J.M., J.L., A.L.K.); Department of Medicine-Endocrinology, Gerontology, & Metabolism (D.N.K., A.R.H., C.D.); and Department of Otolaryngology (A.S., J.A., J.Y.L.), Stanford University School of Medicine, Palo Alto, California, USA. Daniel Kaplan is an endocrinologist now practicing at Epic Care, San Leandro, California, USA.. Electronic address: akossler@stanford.edu.
Anna Needs Neuroblastoma Answers · US

Funding

Stanford Vision Research CoreP30EY026877 · NEI · STANFORD UNIVERSITY · PI Jeffrey L Goldberg · 2017 to 2026
$8.0M
NEI NIH HHS P30 EY026877
6 · The paper itself

Abstract

purposeTo characterize the frequency, severity, and resolution of hearing dysfunction in patients treated with teprotumumab for thyroid eye disease (TED).

designProspective observational case series.

methodsOphthalmic examination and adverse event assessment, including otologic symptoms, were performed at baseline, after infusions 2, 4, and 8, and at 6-month follow-up in consecutive patients who received at least 4 teprotumumab infusions. Laboratory test results were collected at baseline and during treatment. Audiometry, patulous eustachian tube (PET) testing, and otolaryngology evaluation were obtained for patients with new or worsening otologic symptoms, with a subset obtaining baseline and posttreatment testing.

resultsTwenty-seven patients were analyzed (24 females, 3 males, average 56.3 years old). Twenty-two patients (81.5%) developed new subjective otologic symptoms, after a mean of 3.8 infusions (SD 1.8). At 39.2-week average follow-up after the last infusion, most patients with tinnitus (100%), ear plugging/fullness (90.9%), and autophony (83.3%) experienced symptom resolution, whereas only 45.5% (5 of 11) of patients with subjective hearing loss/decreased word comprehension experienced resolution. Six patients underwent baseline and posttreatment audiometry, 5 of whom developed teprotumumab-related sensorineural hearing loss (SNHL) and 1 patient also developed PET. Three of the 5 patients with teprotumumab-related SNHL had persistent subjective hearing loss at last follow-up. A prior history of hearing loss was discovered as a risk factor for teprotumumab-related SNHL (P = .008).

conclusionsHearing loss is a concerning adverse event of teprotumumab, and its mechanism and reversibility should be further studied. Until risk factors for hearing loss are better understood, we recommend baseline audiometry with PET testing and repeat testing if new otologic symptoms develop. Screening, monitoring, and prevention guidelines are needed.

Indexed as

Graves OphthalmopathyHearing LossHearing Loss, SensorineuralAntibodies, Monoclonal, HumanizedAudiometryFemaleHearingHumansMaleMiddle AgedAntibodies, Monoclonal, Humanizedteprotumumab

Identifiers

PMID35227694
PMCPMC9308628
OpenAlexW4214704144

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.